Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Kim S.-B.Maslyar D.J.Dent R.Im S.-A.Espi? M.Blau S.Tan A.R.Isakoff S.J.Oliveira M.Saura C.Wongchenko M.J.Kapp A.V.Chan W.Y.Singel S.M.Baselga J.Kim S.-B.Lee K.S.Im S.-A.Espi? M.Wang H.-C.Blau S.Dent R.Tan A.Sohn J.H.De Laurentiis M.Estevez L.G.CHIUN-SHENG HUANGRomieu G.Velez M.Villanueva R.Conte P.F.Dakhil S.Debled M.Martin A.G.Hurvitz S.Kim J.H.Levy C.Oliveira M.Rovira P.S.Seo J.H.Valero V.Vidal G.Wong A.Allison M.A.K.Figlin R.Chan D.Chen S.-C.Chen Y.-H.Cobleigh M.De Braud F.Dirix L.Hansen V.Bessard A.H.Iannotti N.Isakoff S.Lawler W.Monta?o A.Salkini M.Seigel L.on behalf of the, LOTUS investigators, LOTUS investigatorsLOTUS investigators, LOTUS investigatorson behalf of the2020-03-232020-03-2320171470-2045https://www.scopus.com/inward/record.uri?eid=2-s2.0-85027258099&doi=10.1016%2fS1470-2045%2817%2930450-3&partnerID=40&md5=40dedf22416e8a0796d241d2dc688050https://scholars.lib.ntu.edu.tw/handle/123456789/477714[SDGs]SDG3Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialjournal article10.1016/S1470-2045(17)30450-3288008612-s2.0-85027258099